Plain-English translation of NCT04554277 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Heart Failure research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a blood test called sST-2 can help doctors make better treatment decisions for patients hospitalized with heart failure. Half of the participants will receive standard heart failure care, while the other half will have their sST-2 blood marker checked regularly (at discharge and at 6, 12, 18, and 24 months), and their treatment will be adjusted based on those results. The goal is to see if this personalized approach improves patients' quality of life and reduces hospital readmissions.
Heart failure is a serious condition, and doctors currently treat all patients using standard guidelines. Researchers want to know if regularly measuring this blood marker could help doctors tailor treatment to each individual patient, potentially preventing hospitalizations and improving overall health and well-being.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to either standard heart failure care or care guided by regular blood marker testing. Either way, you'll have clinic visits at 6, 12, 18, and 24 months after enrollment. If you're in the guided treatment group, your doctors will use your blood test results at each visit to adjust your medications and care plan. Throughout the 2-year study, you'll be monitored to see how often you're readmitted to the hospital and how your overall health and quality of life change.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
France